Anti-IL-23 antibodies
AssigneeBoehringer Ingelheim International GmbH
InventorsGerald Henry Nabozny, Annette Bettina Galler, Patrick Garidel, William Troy Loging, Steven John Padula, Torsten Schultz-Fademrecht, Elaine Ee-Ling Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.
Claims32
A pharmaceutical composition comprising an antibody,
- wherein said pharmaceutical composition is an aqueous formulation comprising 90 mg/ml of an anti-IL-23p19 antibody comprising a light chain that comprises the amino acid sequence of SEQ ID NO:174 and a heavy chain that comprises the amino acid sequence of SEQ ID NO:176, 225mM sorbitol, and 4.4mM succinate buffer;
- wherein the pH of said pharmaceutical composition is in the range of pH 5.5 to 6.5 and the osmolarity of said pharmaceutical composition is 300 +/− 30 mOsmol/kg.
A pharmaceutical composition comprising an antibody,
- wherein said pharmaceutical composition is an aqueous formulation comprising 90 mg/ml of an anti-IL-23p19 antibody comprising a light chain that comprises the amino acid sequence of SEQ ID NO:174 and a heavy chain that comprises the amino acid sequence of SEQ ID NO:176 and 240mM sorbitol;
- wherein the pH of said pharmaceutical composition is in the range of pH 5.5 to 6.5 and the osmolarity of said pharmaceutical composition is 300 +/− 30 mOsmol/kg.
A liquid aqueous pharmaceutical formulation comprising (a) an anti-IL23p19 antibody in a concentration of 90 mg/ml, (b) a detergent, and (c) a tonicity agent, wherein the anti-IL23p19 antibody comprises a light chain amino acid sequence shown as SEQ ID NO:174 and a heavy chain amino acid sequence shown as SEQ ID NO:176, wherein the formulation is stable, isotonic, has a pH in the range of 5.5 to 6.5, and wherein the formulation optionally comprises a buffer.
A liquid aqueous pharmaceutical formulation comprising (a) an anti-IL23p19 antibody, (b) a detergent, and (c) a tonicity agent, wherein the anti-IL23p19 antibody comprises a light chain amino acid sequence shown as SEQ ID NO:174 and a heavy chain amino acid sequence shown as SEQ ID NO:176, wherein the formulation is stable, isotonic, has a pH in the range of 5.5 to 6.5, and wherein the formulation optionally comprises a buffer.
Dependencies are inferred from the claim text.